BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24295895)

  • 1. Use of oxcarbazepine for treatment of refractory status epilepticus.
    Kellinghaus C; Berning S; Stögbauer F
    Seizure; 2014 Feb; 23(2):151-4. PubMed ID: 24295895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children.
    Holtmann M; Krause M; Opp J; Tokarzewski M; Korn-Merker E; Boenigk HE
    Neuropediatrics; 2002 Dec; 33(6):298-300. PubMed ID: 12571784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy.
    Lin CH; Lu CH; Wang FJ; Tsai MH; Chang WN; Tsai NW; Lai SL; Tseng YL; Chuang YC
    Clin Neuropharmacol; 2010; 33(6):293-6. PubMed ID: 20881597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous lacosamide in status epilepticus and seizure clusters.
    Höfler J; Unterberger I; Dobesberger J; Kuchukhidze G; Walser G; Trinka E
    Epilepsia; 2011 Oct; 52(10):e148-52. PubMed ID: 21801171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy.
    Dogan EA; Usta BE; Bilgen R; Senol Y; Aktekin B
    Epilepsy Behav; 2008 Jul; 13(1):156-61. PubMed ID: 18331816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies.
    Gelisse P; Genton P; Kuate C; Pesenti A; Baldy-Moulinier M; Crespel A
    Epilepsia; 2004 Oct; 45(10):1282-6. PubMed ID: 15461683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice.
    Pauletto G; Bergonzi P;
    Seizure; 2006 Apr; 15(3):150-5. PubMed ID: 16439165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
    Park KJ; Kim JR; Joo EY; Seo DW; Hong SB; Ko JW; Kim SR; Huh W; Lee SY
    Clin Neuropharmacol; 2012; 35(1):40-4. PubMed ID: 22246398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxcarbazepine long-term treatment retention in patients switched over from carbamazepine.
    Albani F; Baruzzi A;
    Neurol Sci; 2006 Jul; 27(3):173-5. PubMed ID: 16897629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxcarbazepine-induced myoclonic status epilepticus in juvenile myoclonic epilepsy.
    Fanella M; Egeo G; Fattouch J; Casciato S; Lapenta L; Morano A; Giallonardo AT; Di Bonaventura C
    Epileptic Disord; 2013 Jun; 15(2):181-7. PubMed ID: 23774821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy.
    Berghuis B; van der Palen J; de Haan GJ; Lindhout D; Koeleman BPC; Sander JW;
    Epilepsia; 2017 Jul; 58(7):1227-1233. PubMed ID: 28542738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retention rate of oxcarbazepine monotherapy in an unselected population of adult epileptics.
    Rainesalo S; Peltola J; Auvinen A; Keränen T
    Seizure; 2005 Jan; 14(1):72-4. PubMed ID: 15642505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy.
    Kowalik A; Rimpau W; Adam H; Kühn F; van Oene J; Schreiner A; Bogdanow M; Schauble B;
    Acta Neurol Scand; 2008 Mar; 117(3):159-66. PubMed ID: 18218062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggravation of seizures and/or EEG features in children treated with oxcarbazepine monotherapy.
    Vendrame M; Khurana DS; Cruz M; Melvin J; Valencia I; Legido A; Kothare SV
    Epilepsia; 2007 Nov; 48(11):2116-20. PubMed ID: 17645535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyponatremic coma under oxcarbazepine therapy.
    Steinhoff BJ; Stoll KD; Stodieck SR; Paulus W
    Epilepsy Res; 1992 Mar; 11(1):67-70. PubMed ID: 1563340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of status epilepticus in a large community hospital.
    Kellinghaus C; Stögbauer F
    Epilepsy Behav; 2012 Mar; 23(3):235-40. PubMed ID: 22341964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia.
    Kim YS; Kim DW; Jung KH; Lee ST; Kang BS; Byun JI; Yeom JS; Chu K; Lee SK
    Seizure; 2014 Mar; 23(3):208-12. PubMed ID: 24378204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oxcarbazepine].
    Arroyo S
    Neurologia; 2001 Oct; 16(8):370-5. PubMed ID: 11738014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.
    Mintzer S; Boppana P; Toguri J; DeSantis A
    Epilepsia; 2006 Mar; 47(3):510-5. PubMed ID: 16529614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study.
    Garcés M; Villanueva V; Mauri JA; Suller A; García C; López González FJ; Rodríguez Osorio X; Fernández Pajarín G; Piera A; Guillamón E; Santafé C; Castillo A; Giner P; Torres N; Escalza I; Del Villar A; García de Casasola MC; Bonet M; Noé E; Olmedilla N
    Epilepsy Behav; 2014 Jul; 36():144-52. PubMed ID: 24922617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.